Author

B. Theivanthiran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

B. A. Hanks· 2 shared G. Beasley· 2 shared M. P. Plebanek· 2 shared N. Yarla· 2 shared Y.-V. Nguyen· 2 shared A. Holtzhausen· 1 shared K. Howell· 1 shared M. Aksu· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. A. Hanks

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

N. C. DeVito, Y.-V. Nguyen, M. Sturdivant, M. P. Plebanek, K. Howell, N. Yarla, V. Jain, M. Aksu, G. Beasley, B. Theivanthiran, B. A. Hanks

This paper identifies Gli2 as a key driver of immune evasion and immunotherapy resistance in tumors through Wnt and prostaglandin signaling, offering a therapeutic target for combination immunotherapies.

bioRxiv · Mar 31, 2024Cancer Biology

A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression

M. P. Plebanek, Y. Xue, Y.-V. Nguyen, N. DeVito, X. Wang, A. Holtzhausen, G. Beasley, N. Yarla, B. Theivanthiran, B. A. Hanks

The paper identifies SREBF2 as a regulator of mregDC development and function in the tumor microenvironment, highlighting it as a therapeutic target for immune tolerance.

bioRxiv · Apr 26, 2023 · PreprintImmunology